Welcome to our dedicated page for Renovorx SEC filings (Ticker: RNXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RenovoRx, Inc. (RNXT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, registration statements, and other documents filed with the U.S. Securities and Exchange Commission. RenovoRx is a life sciences company developing targeted oncology therapies and commercializing RenovoCath®, an FDA‑cleared local drug‑delivery device enabled by its patented Trans‑Arterial Micro‑Perfusion (TAMP™) therapy platform.
Through its SEC filings, RenovoRx reports financial results, commercialization progress for RenovoCath, and updates on its clinical development programs. For example, Form 8‑K filings have referenced quarterly financial press releases that discuss revenue from RenovoCath sales, expansion of cancer center customers, and advancement of the Phase III TIGeR‑PaC trial evaluating intra‑arterial gemcitabine (IAG) delivered via RenovoCath in locally advanced pancreatic cancer.
Filings also describe capital markets activity. In a Form 8‑K dated November 14, 2025, RenovoRx reported entering into a Capital on Demand™ Sales Agreement with a sales agent, allowing the company to issue and sell shares of common stock in at‑the‑market offerings or negotiated transactions under an effective shelf registration statement on Form S‑3. Related exhibits include the sales agreement and a legal opinion on the validity of the shares.
On Stock Titan, users can review these filings alongside AI‑generated highlights that help explain key sections, such as risk factor updates, financing terms, and business strategy disclosures. Investors can also monitor current reports that incorporate press releases detailing clinical milestones, registry studies, Scientific Advisory Board changes, and commercialization strategy for RenovoCath and the TAMP platform.
In addition, this page is a starting point for tracking RenovoRx’s ongoing reporting obligations, including future quarterly and annual reports, as well as any additional Forms 8‑K that may discuss clinical trial developments, capital raises, or changes in governance.
RenovoRx, Inc. (Nasdaq: RNXT) filed a Form 8-K to report the voting results of its 2025 Annual Meeting held on 24 June 2025. Of the 36,551,752 shares outstanding on the 25 April 2025 record date, approximately 20,086,518 shares (55%) were present or represented by proxy, satisfying quorum requirements.
Proposal 1 – Director Elections: All seven nominees were elected to one-year terms expiring at the 2026 meeting. Four directors (Bagai, Agah, Macfarlane) received ~13.0 million votes each with minimal withholds, while three directors (Marton, Ryan, Spiegel) received ~9.5-9.9 million votes and ~3.3-3.6 million withholds. Broker non-votes were 6.95 million for every nominee.
Proposal 2 – Equity Incentive Plan Amendments: Shareholders approved (i) reserving an additional 913,794 shares (2.5% of outstanding) for the 2021 Omnibus Equity Incentive Plan and (ii) raising the plan’s evergreen provision from 3% to 5% of year-end shares. Votes: 9,056,181 for; 4,037,698 against; 38,379 abstentions; 6,954,260 broker non-votes.
Proposal 3 – Auditor Ratification: Frank, Rimerman + Co. LLP was ratified as independent auditor for FY 2025 with strong support (19,131,750 for; 949,070 against; 5,698 abstentions).
The filing discloses no financial performance metrics or strategic transactions but confirms routine corporate governance matters, an expanded share reserve for equity compensation, and continuity of external audit oversight.